Flavocoxid

WikiDoc Resources for Flavocoxid
Articles
Most recent articles on Flavocoxid Most cited articles on Flavocoxid Review articles on Flavocoxid Articles on Flavocoxid in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Flavocoxid Images of Flavocoxid Photos of Flavocoxid Podcasts & MP3s on Flavocoxid Videos on Flavocoxid
Evidence Based Medicine
Cochrane Collaboration on Flavocoxid Bandolier on Flavocoxid TRIP on Flavocoxid
Clinical Trials
Ongoing Trials on Flavocoxid at Clinical Trials.gov Trial results on Flavocoxid Clinical Trials on Flavocoxid at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Flavocoxid NICE Guidance on Flavocoxid NHS PRODIGY Guidance FDA on Flavocoxid CDC on Flavocoxid
Books
Books on Flavocoxid
News
Flavocoxid in the news Be alerted to news on Flavocoxid News trends on Flavocoxid
Commentary
Blogs on Flavocoxid
Definitions
Definitions of Flavocoxid
Patient Resources / Community
Patient resources on Flavocoxid Discussion groups on Flavocoxid Patient Handouts on Flavocoxid Directions to Hospitals Treating Flavocoxid Risk calculators and risk factors for Flavocoxid
Healthcare Provider Resources
Symptoms of Flavocoxid Causes & Risk Factors for Flavocoxid Diagnostic studies for Flavocoxid Treatment of Flavocoxid
Continuing Medical Education (CME)
CME Programs on Flavocoxid
International
Flavocoxid en Espanol Flavocoxid en Francais
Business
Flavocoxid in the Marketplace Patents on Flavocoxid
Experimental / Informatics
List of terms related to Flavocoxid

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Flavocoxid is a brand name for a blend of flavenoids that has recently become a tool in the treatment of osteoarthritis. It is sold under the brand name Limbrel, manufactured by Primus Pharmaceuticals. The capsules also include the ingredient zinc gluconate. Limbrel is used as a nutritional therapy to help reduce inflammation. Flavocoxid has been associated with liver toxicity in prospective clinical trials published in the Annals of Internal Medicine.